CTOs on the Move

Medical Resources Network

www.medres.net

 
Medical Resources Network is a Portland, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.medres.net
  • 10725 SW Barbur Blvd Ste 200
    Portland, OR USA 97219
  • Phone: 503.452.1748

Executives

Name Title Contact Details

Similar Companies

Advanced Health Education Center

Advanced Health Education Center is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AssistMed

AssistMed is a Beverly Hills, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ACT Center of Indiana

ACT Center of Indiana is a Indianapolis, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Soar Autism Center

Soar Autism Center is a Colorado-based organization that provides evidence-based therapy for young children with autism. They offer a whole child therapy plan including ABA therapy, speech therapy, occupational therapy, and psychological care.

Bionor Pharma

Bionor Pharma is a leading biotechnology company advancing the first therapeutic vaccine towards a functional cure for HIV. The company`s focus is the research and development of peptide-based vaccines against viral diseases, primarily HIV. Bionor Pharma`s most advanced product candidate is Vacc-4x, which is also the most advanced therapeutic vaccine in the HIV space and has demonstrated a reduction of viral load in a large, randomized, controlled Phase II trial, as well as safety and tolerability. Pharma`s current clinical focus is to explore whether Vacc-4x, used with other medicines as a combination therapy, can reduce the viral load even further, and the company, through collaboration with Celgene, is investigating Vacc-4x and the HDAC inhibitor romidepsin in the REDUC study. In May 2015, Bionor Pharma announced promising results from an interim analysis of Part B of the REDUC study. In the study, Vacc-4x and romidepsin are explored as a possible treatment regimen to reduce the persistent latent viral reservoir in HIV infected patients on anti-retroviral treatment. Results are expected in the second half of 2015. Bionor Pharma is headquartered in Oslo, Norway, with offices in Copenhagen and New York.